Showing 2281-2290 of 5064 results for "".
First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.Remibrutinib For Treating Chronic Spontaneous Urticaria
https://practicaldermatology.com/videos/skin-minute/remibrutinib-for-treating-chronic-spontaneous-urticaria/60980/Marty Metz, MD, explores and reflects on results from the REMIX 1 and 2 studies, which evaluated the impact of remibrutinib (Rhapsido, Novartis) on symptom relief and control of chronic spontaneous urticaria (CSU).DERM2020 NP/PA CME Conference Thank You from DEF President Joe Gorelick, MSN, FNP-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-nppa-cme-conference-thank-you/19837/Joe Gorelick thanks the participants for DERM2020 Session 1 – all live webinars from August 6 – 11, 2020!Long-term efficacy and safety data from ILUMYA™ clinical trials
https://practicaldermatology.com/topics/psoriasis/long-term-efficacy-and-safety-data-from-ilumya-clinical-trials/19858/Explore efficacy and safety data for ILUMYA™ from the reSURFACE 1 and reSURFACE 2 Phase 3 trials and extension studies.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tA Case of Deductible Reasoning and Social Media Extortion
https://practicaldermatology.com/topics/practice-management/a-case-of-deductible-reasoning-and-social-media-extortion/21201/Key Lessons for Surviving COVID-19 as a Dermatologist
https://practicaldermatology.com/topics/practice-management/key-lessons-for-surviving-covid-19-as-a-dermatologist/23405/Here are 10 lessons we learned about crisis preparedness from leading dermatologists.Facing Challenges: Adapting Practice in the Face of COVID-19
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/facing-challenges-adapting-practice-in-the-face-of-covid-19/23266/CSF Faculty share experiences and tips for practicing in the “new normal.”Origins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).